Detecting plasma Epstein-barr virus DNA to diagnose postradiation nasopharngeal skull base lesions in nasopharyngeal carcinoma patients: A prospective study

Chinese Journal of Cancer

Volumn 31, Issue 3, 2012, Pages 142-149

  Liang, Fa Ya ^a   Sun, Wei ^a   Han, Ping ^a   Lu, Xing ^a   Lian, Ying Ni ^b   Huang, Xiao Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Department of Oncology   (China)

Author keywords

Diagnostic test; Endoscopic surgery; Nasopharyngeal carcinoma; Plasma EBV DNA; Postradiation lesions

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOSCOPIC SURGERY; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; OSTEORADIONECROSIS; PROSPECTIVE STUDIES; SKULL BASE;

EID: 84857951927     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10279     Document Type: Article

References (28)

1. Shin HR, Masuyer E, Ferlay J, et al. Cancer in Asia--Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev, 2010,11:11-16.
2. Smee RI, Meagher NS, Broadley K, et al. Recurrent nasopharyngeal carcinoma: current management approaches. Am J Clin Oncol, 2010,33:469-473.
3. Ng SH, Chang JT, Ko SF, et al. MRI in recurrent nasopharyngeal carcinoma. Neuro radiology, 1999,41:855-862.
4. Liu T, Xu W, Yan WL, et al. FDG-PE T, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol, 2007,85:327-335.
5. Lu TX, Mai WY, Teh BS, et al. Initial experience using intensity- modulated radiotherapy for recurrent nasopharyngeal carci- noma. Int J Radiat Oncol Biol Phys, 2004,58:682-687.
6. King AD, Ahuja AT, Leung SF, et al. MR imaging of nonmalignant polyps and masses of the nasopharynx and sphenoid sinus after radiotherapy for nasopharyngeal carcinoma. AJNR Am J Neuroradiol, 2008,29:1209-1214.
7. Lell M, Baum U, Greess H, et al. Head and neck tumors: imaging recurrent tumor and post-th erapeutic changes with CT and MRI. Eur J Radiol, 2000,33:239-247.
8. Hung GU, Tsai SC, Lin WY. Extraordinarily high F-18 FDG uptake caused by radiation necrosis in a patient with nasopharyngeal carcinoma. Clin Nucl Med, 2005,30:558-559.
9. Liu SH, Chang JT, Ng SH, et al. False positive fluorine-18 fluorodeoxy-D-gl ucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol, 2004,77:257-260.
10. Yen RF, Ting LL, Cheng MF, et al. Usefulness of 201TL SPECT/CT relative to 18F-FD G PET/CT in detecting recurrent skull base nasopharyngeal carcinoma. Head Neck, 2009,31: 717-724.
11. Siepmann DB, Siegel A, Lewis PJ. Tl-20 1 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis. Clin Nucl Med, 2005,30:199-200.
12. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-B arr virus DNA in patients with advanced nasopharyn-geal carcinoma. N Engl J Med, 2004,350:2461-2470.
13. An X, Wang FH, Ding PR, et al. Plasma Epstein-B arr virus DNA level strongly predicts survival in meta static/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer, 2011,117:3750-3753 757.
14. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-B arr viral deoxyribonucleic acid quantitation complements tumor-no de-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol, 2006,24:5414-5418.
15. Li YH, Shao JY, Zhao MQ, et al. Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy. Ai Zheng, 2003,22:645-648. [in Chinese]
16. Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein- Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/ virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer, 2004,100:1162-1170.
17. Ng SH, Chan SC, Yen TC, et al. Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-bo dy MRI at 3 T compared with FDG-PE T-CT. Eur Radiol, 2010,20:2229-2240.
18. Huang XM, Zheng YQ, Zhang XM, et al. Diagnosis and management of skull base osteoradionecrosis after radiotherapy for nasopharyngeal carcinoma. Laryngoscope, 2006,116:1626-1631.
19. Bronstein AD, Nyberg DA, Schwartz AN, et al. Soft-tis sue changes after head and neck radiation: CT findings. AJNR Am J Neuroradiol, 1989,10:171-175.
20. Kao CH, Shiau YC, Shen YY, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99 m methoxy is obutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-flu oro-2- de oxyglucose positron emission tomography. Cancer, 2002,94:1981-1986.
21. Yen RF, Hung RL, Pan MH, et al. 18-flu oro-2- de oxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer, 2003,98:283-287.
22. King AD, Griffith JF, Abrigo JM, et al. Osteo radionecrosis of the upper cervical spine: MR imaging following radiotherapy for nasopharyngeal carcinoma. Eur J Radiol, 2010,73:629-635.
23. Yen RF, Hong RL, Tzen KY, et al. Whole-bo dy 18F-FD G PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med, 2005,46:770-774.
24. Fischbein NJ, Aassar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-flu orodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol, 1998,19:1189-1196.
25. Zeng L, Huang XM, Lu TX, et al. Diagnosis of recurrent or residual nasopharyngeal carcinomas in the skull base area with F-18-fluoro-de oxyglucose positron emission tomography. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2006,41: 517-520. [in Chinese]
26. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-B arr viral DNA in serum of patients with nasopharyn- geal carcinoma. Clin Cancer Res, 1998,4:665-669.
27. Shotelersuk K, Khorprasert C, Sakdikul S, et al. Epstein-B arr virus DNA in serum/plasma as a tumor marker for nasopharyn- geal cancer. Clin Cancer Res, 2000,6:1046-1051.
28. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell- free Epstein-B arr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 1999,59:1188-1191.